Crescent Biopharma, Inc. (CBIO)

NASDAQ: CBIO · USD

$13.5

+0.23 (+1.7%)· Recorded snapshot

Market cap	577.8M
Revenue (ttm)	11.9M
Net income (ttm)	-165.1M
EPS (ttm)	-$6.03
Shares out	42.8M
Volume	190,552

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 11.9M
Net income (ttm): -165.1M
EPS (ttm): -$6.03
Market cap: 577.8M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	持有

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROEn/a

P25 n/aP50 n/aP75 n/a

ROICn/a

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All CBIO indicators

Market & fundamental data

Available fields

169

Groups with data

Currency

USD

Showing 169 of 169 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001253689
Company name	Crescent Biopharma, Inc.
Country	United States
Country code	US
CUSIP number	G2545C104
Earnings date	2026-11-09
Earnings time	bmo
Employees	69
Employees change	36
Employees growth	109.09%
Enterprise value	$407.7M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2003
In index	RUSSELL2000
Industry	Biotechnology
Is primary listing	Yes
Is SPAC	No
ISIN number	KYG2545C1042
Last 10-K release date	2026-03-13
Last earnings date	2026-07-30
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$577.8M
Market cap category	Small-Cap
Next earnings date	2026-11-09
Options	Yes
Price	$13.50
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	CBIO
U.S. state	Massachusetts
Website	https://crescentbiopharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-44.67%
EV/Sales	33.77x
FCF / EV yield	-18.35%
FCF yield	-12.88%
Forward EV/Sales	561.74x
Forward P/S	799.96x
P/B ratio	2.78x
P/S ratio	48.09x
Price / tangible book value	3.59x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	100%
Operating margin	-1,432.63%
Pretax margin	-1,372.75%
Profit per employee	$-2.4M
Revenue per employee	$172,217
ROCE	-103.67%
SBC / revenue	124.62%
Tax / revenue	16.83%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	5
EPS growth years	1
Net income growth years	0
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-939,000
Depreciation and amortization	$212,000
EBIT	$-170.2M
EBITDA	$-170M
EPS	$-6.03
FCF per share	$-1.72
Financing cash flow	$170.8M
Free cash flow	$-73.6M
Free cash flow minus SBC	$-88.4M
Gross profit	$11.9M
Income taxes	$2M
Investing cash flow	$-79.2M
Net cash flow	$18.9M
Net income	$-165.1M
Operating cash flow minus SBC	$-87.5M
Operating income	$-170.2M
Revenue	$11.9M
Stock-based compensation	$14.8M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	7.44
Book value per share	$4.77
Debt / equity	0.01
Long-term assets	$3.8M
Long-term liabilities	$966,000
Net cash (debt)	$170.2M
Net cash / market cap	29.78%
Net cash growth	12.69%
Net debt / equity	-1.04
Piotroski F-Score	1
Property, plant and equipment	$2.1M
Shareholders' equity	$163.3M
Tangible book value	$159.3M
Tangible book value per share	$4.77
Total assets	$182.8M
Total cash	$171.6M
Total debt	$1.4M
Total liabilities	$19.5M

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$179M
Current liabilities	$18.5M
Current ratio	9.66
Net working capital	$-10.7M
Quick ratio	9.26
Working capital	$160.5M
Working capital turnover	0.08

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Dividend yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$17.43
1D price change	1.73%
1M price change	-5.33%
1M total return	-5.33%
1W price change	1.34%
1W total return	1.34%
1Y price change	1.89%
1Y return CAGR	1.89%
1Y total return	1.89%
20-day SMA	$13.34
200-day SMA	$15.87
3M price change	-21.77%
3M total return	-21.77%
50-day SMA	$15.74
50-day SMA vs 200-day SMA	50under200
52-week high	$27.41
52-week high date	2026-04-22
52-week low	$8.72
52-week low date	2026-02-09
6M price change	-47.34%
6M total return	-47.34%
All-time high	$27.41
All-time high date	2026-04-22
All-time low	$8.72
All-time low date	2026-02-09
Average true range (ATR)	$1.06
Average volume	303.6K
Beta (1Y)	1.81
Beta (2Y)	1.88
Change from 52-week high	-50.75%
Change from 52-week low	54.82%
Change from all-time high	-51.68%
Change from all-time low	51.89%
Change from open	1.2%
Day's gap	0.53%
Dollar volume	$2.6M
High price	$13.59
Low price	$13.09
Monthly RSI	48.63
Open price	$13.34
Position in 52-week range	82%
Previous close	$13.27
Price vs 150-day SMA	-23.99%
Price vs 20-day SMA	-0.68%
Price vs 200-day SMA	-16.52%
Price vs 50-day SMA	-15.84%
Relative volume	0.63
RSI	43.48
Sharpe ratio	0.37
Sortino ratio	0.64
Volume	190.6K
Weekly RSI	43.64
YTD price change	11.68%
YTD total return	11.68%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	27M
Float percentage	63.15%
Shares change (QoQ)	0.4%
Shares held by insiders	3.86%
Shares held by institutions	57.08%
Shares outstanding	42.8M
Short % of float	17.67%
Short % of shares	11.16%
Short ratio	8.8 days

Deeper analysis on CBIO

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this CBIO report

Is a complete CBIO research report available?

No complete published report is available for Crescent Biopharma, Inc. (CBIO) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Crescent Biopharma, Inc. (CBIO)

Price

Financial snapshot

Fair-value bridge

Latest news · CBIO

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All CBIO indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on CBIO

Frequently asked questions